PHB2 and endometrial cancer: In addition, stERAP-6 may provide long-lasting suppressive activity in ERα-negative breast cancer and endometrial cancer, because BIG3 and PHB2 are significantly overexpressed in some ERα-negative breast cancers9, and patients with endometrial cancer based on the RNAseq dataset from the Cancer Genome Atlas and Gene Expression Omnibus database (Supplementary Fig. S3j).